Investigational drug · Phase 2
JBI-802
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Essential Thrombocythemia (ET), Polycythemia Vera.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "JBI-802"
First trial start
2024
Oct 21, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "JBI-802", any sponsor or status.
Conditions studied
As listed on its trial records.
- Essential Thrombocythemia (ET)
- Polycythemia Vera
Approved drugs for the same conditions: Hematology and blood cancers · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "JBI-802" as an intervention, largest first.
- A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid TumorsStatus unknown
Jubilant Therapeutics Inc.Industry
NCT05268666 · 126 participants (planned) · Start Apr 8, 2022 · Primary completion Dec 2024
Drug: JBI-802 · For: Locally Advanced Solid Tumor; Metastatic Solid Tumor
Sites: Denver, Colorado; Cincinnati, Ohio; Nashville, Tennessee · 4 sites in all
Jubilant Therapeutics Inc.Industry
NCT07612280 · 70 participants (planned) · Start Oct 21, 2024 · Primary completion Jan 30, 2031
Drug: JBI-802 · For: Essential Thrombocythemia (ET); Polycythemia Vera
Sites: Sydney, Australia; Adelaide, Australia; Melbourne, Australia · 7 sites in all
The Christ HospitalAcademic, hospital or other
NCT07207395 · 30 participants (planned) · Start Apr 29, 2025 · Primary completion Oct 2027
Drug: JBI-802; Pembrolizumab · For: Lung Cancer (NSCLC)
Sites: Cincinnati, Ohio
Newest research
PubMed records naming it or its code names, newest first.
- JBI-802: the first orally available LSD1/HDAC6 dual inhibitor to enter clinical trials.
Zhang J, Ren X, Song Y, et al. · Expert Opin Ther Pat 2025
- Combination Therapy and Dual-Target Inhibitors Based on LSD1: New Emerging Tools in Cancer Therapy.
Shen L, Wang B, Wang SP, et al. · J Med Chem 2024
- LSD1 inhibitors for cancer treatment: Focus on multi-target agents and compounds in clinical trials.
Noce B, Di Bello E, Fioravanti R, et al. · Front Pharmacol 2023
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.